Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02017860
- Locations
- 🇯🇵
Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02015663
- Locations
- 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT02014636
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
Phase 3
Terminated
- Conditions
- Acute Heart Failure
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 876
- Registration Number
- NCT02007720
- Locations
- 🇹🇭
Novartis Investigative Site, Muang, Thailand
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
Phase 3
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 226
- Registration Number
- NCT02008916
- Locations
- 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Phase 3
Completed
- Conditions
- Palmoplantar Pustular Psoriasis
- Interventions
- Biological: Secukinumab 300mgBiological: PlaceboBiological: Secukinumab 150mg
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 237
- Registration Number
- NCT02008890
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Phase 4
Completed
- Conditions
- HypoglycemiaType 2 Diabetes
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02007278
- Locations
- 🇨🇴
Novartis Investigative Site, Monteria, Colombia
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT02007252
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
Terminated
- Conditions
- Wet Age-related Macular Degeneration
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT02005133
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT02002702
- Locations
- 🇯🇵
Novartis Investigative Site, Itabashi-ku, Tokyo, Japan